Brief: Tiziana Life Sciences Announces IND Filed For Phase 2 Study Of Milciclib
04/01/2023 12:42
Jan 4 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES ANNOUNCES IND FILED FOR PHASE 2
STUDY OF
MILCICLIB IN COMBINATION WITH GEMCITABINE FOR NON-SMALL CELL
LUNG CANCER
Source text for Eikon: ID:nGNX2s2VxJ
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study